1.94
price up icon14.12%   0.24
after-market アフターアワーズ: 1.94
loading

なぜBluejay Diagnostics Inc(BJDX)の株価が下がっていますか?

2025-04-25 の取引セッション中に、Bluejay Diagnostics Inc (BJDX) 株の 5.49% 下落を確認しました。これは通常のボラティリティやさまざまな内部および外部要因に起因する可能性がありますが、当社では状況を積極的に監視しており、できるだけ早くタイムリーな最新情報を提供することに注意してください。
2023-12-28:

Bluejay Diagnostics Inc (BJDX) stock dropped by 32.48% due to public offering, which typically dilutes the value of existing shares, and concerns about the company's financial health. Additionally, while clinical studies can be positive for the long-term prospects of a medical technology company, they often involve substantial costs and may not yield immediate financial benefits.

  • Public Offering Announcement: Bluejay Diagnostics announced a public offering of 2,692,308 shares of the company's common stock (or pre-funded warrants) and warrants to purchase up to 2,692,308 shares at a combined offering price of $1.30 per share (or pre-funded warrant). The warrants will have an exercise price of $1.30 per share and will be exercisable for five years. The gross proceeds to the company from the offering are expected to be approximately $3.5 million, which will be used for various purposes, including obtaining FDA approval, clinical studies, research and development, and working capital needs.
  • Clinical Study Initiation: Bluejay Diagnostics initiated a multicenter clinical study called the SYMON study to evaluate the Symphony IL-6 test in sepsis patients. The Symphony System is designed to provide rapid quantitative measurements of specific biomarkers to determine the need for additional patient care and monitoring. Sepsis is a significant medical issue, and the study aims to assess the effectiveness of the Symphony IL-6 test in predict
medical_devices ZBH
$102.79
price up icon 1.01%
medical_devices STE
$224.04
price down icon 0.54%
medical_devices PHG
$25.03
price down icon 0.91%
$71.30
price up icon 0.17%
$68.09
price up icon 0.03%
medical_devices EW
$76.28
price up icon 0.98%
大文字化:     |  ボリューム (24 時間):